920757-35-3 Usage
Uses
Used in Pharmaceutical Industry:
Valine, N-(Methoxy-d3-carbonyl)-3-Methylis used as a labeled analogue for [application reason] in the pharmaceutical industry. Its incorporation of a deuterium atom allows for the study of metabolic pathways, drug interactions, and the development of new therapeutic agents.
Used in Research Applications:
In research, Valine, N-(Methoxy-d3-carbonyl)-3-Methylis used as a stable isotope-labeled compound for [application reason]. This enables researchers to track the compound's behavior in biological systems, monitor its metabolism, and investigate its potential effects on various biological processes.
Used in Drug Development:
Valine, N-(Methoxy-d3-carbonyl)-3-Methylis used as a reference compound for [application reason] in drug development. Its unique properties make it a valuable tool for assessing the efficacy and safety of new drug candidates, as well as for optimizing their pharmacokinetic and pharmacodynamic profiles.
Used in Mass Spectrometry:
In mass spectrometry, Valine, N-(Methoxy-d3-carbonyl)-3-Methylis used as an internal standard for [application reason]. The presence of the deuterium atom provides a distinct mass signature, allowing for accurate quantification and identification of related compounds in complex samples.
Check Digit Verification of cas no
The CAS Registry Mumber 920757-35-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,0,7,5 and 7 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 920757-35:
(8*9)+(7*2)+(6*0)+(5*7)+(4*5)+(3*7)+(2*3)+(1*5)=173
173 % 10 = 3
So 920757-35-3 is a valid CAS Registry Number.
920757-35-3Relevant academic research and scientific papers
Azapeptide derivatives as HIV protease inhibitors
-
Page/Page column 40, (2009/01/24)
This invention relates to novel compounds of the Formula Ib: that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering HIV protease inhibitors. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving atazanavir.
A facile and efficient synthesis of d3-labelled Reyataz
Zhang, Huiping,Bonacorsi Jr., Samuel J.,Chen, Bang-Chi,Leith, Leslie W.,Rinehart, J. Kent,Balasubramanian, Balu,Barrish, Joel C.
, p. 1041 - 1047 (2007/10/03)
A facile and efficient synthesis of d3-labelled Reyataz is described. The key step of synthesis involved the coupling of N-(d 3-methoxycarbonyl)-L-tert-leucine 2b with an advanced chiral non-racemic building block 4. The latter was synthesized in 4 steps from the readily accessible hydrazine derivative 8. Copyright
